相关研究结果发表在2021年8月5日的NEJM期刊上,论文标题为“CD19-Targeted CAR T Cells in Refractory Systemic Lupus Erythematosus”。 系统性红斑狼疮是一种自身免疫性疾病,可导致全身器官损伤。论文通讯作者、埃朗根-纽伦堡大学的Georg Schett博士说,这名女性是世界上第一个用CAR-T细胞治疗的狼疮患者。这意味着在这...
[6] Mougiakakos, D. et al. CD19-targeted CAR T cells in refractory systemic lupuserythematosus. N. Engl. J. Med. 385, 567–569 (2021). [7] . Kalos, M. et al. T cells with chimeric antigen receptors have potent antitumor efects and ...
2024 AACR: CT244 / 3 - HR001, a novel CD19-targeted CAR-T cell therapy for patients with relapsed/refractory non-Hodgkin's lymphoma: primary results of a phase II study (HRAIN01-NHL01-II) 声明 本资讯旨在帮...
Bispecific BCMA/CD19 targeted CAR-T cell therapy forces sustained disappearance of symptoms and anti-acetylcholine receptor antibodies in refractory myasthenia gravis: a case reportMYASTHENIA gravisRECEPTOR antibodiesCELLULAR therapyLEUCOCYTESBONE marrow cells...
3.Gauthier, J. et al. Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B cell malignancies. Blood网页链接(2020). 4.Maus, M. V. et al. T cells expressing chimeric antigen receptors can cause anaphylaxis in humans. Cancer Immunol. Res. 1, ...
CD19-targeted CAR T cells have induced complete remissions of disease in up to 90% of patients with relapsed or refractory B-cell acute lymphoblastic leukemia (B-ALL), who have an expected complete response rate of 30% in response to chemotherapy. The high efficacy of CAR T cells in B-...
The kinetics of CAR-T cells in vivo were linked to an increase in the expression of genes related to immune response and cytolysis/cytotoxicity.Similar content being viewed by others CD19/BAFF-R dual-targeted CAR T cells for the treatment of mixed antigen-negative variants of acute ...
2024年4月20日,徐州医科大学附属医院血液科曹江、徐开林团队与徐州医科大学细胞治疗药物产业学院郑骏年、施明团队合作,在国际知名期刊 Nature Communications (中科院1区top,IF=16.6)发表了题为“Bispecific CAR T-cell therapy targeting BCMA and CD19 in relapsed/refractory multiple myeloma: a phase I/II trial”...
Despite the high therapeutic response achieved with B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapy in relapsed and refractory multiple myeloma (R/R MM), primary resistance and relapse exist with single-target immunotherapy. Here, we design bispecific BC19 ...
OBJECTIVE To investigate the efficacy and adverse reaction of CD19-targeted chimeric antigen receptor T cells (CAR-T)in the treatment of relapsed/refractory diffuse large B-cell lymphoma(R/R DLBCL),so as to provide an evidence-based basis for more reasonable and efficient application of CAR-T....